Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
700 participants
Mar 15, 2025
INTERVENTIONAL
Conditions
Summary
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of disease or unacceptable toxicities arise.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
A recombinant protein comprised of the soluble form of human receptor EphB4 fused to human serum albumin.
Antibody to human PD-1.
A chemotherapy drug used to treat various types of cancer.
A type of chemotherapy drug called an alkylating agent used to treat various types of cancer.
Nectin-4-directed antibody and microtubule inhibitor conjugate.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06493552